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Abstract: Being naturally enriched in key nutrients and in various health-promoting 
compounds, seaweeds represent promising candidates for the design of functional foods. 
Soluble dietary fibers, peptides, phlorotannins, lipids and minerals are macroalgae’s major 
compounds that can hold potential in high-value food products derived from macroalgae, 
including those directed to the cardiovascular-health promotion. This manuscript revises 
available reported data focusing the role of diet supplementation of macroalgae, or extracts 
enriched in bioactive compounds from macroalgae origin, in targeting modifiable markers 
of cardiovascular diseases (CVDs), like dyslipidemia, oxidative stress, vascular 
inflammation, hypertension, hypercoagulability and activation of the sympathetic and 
renin-angiotensin systems, among others. At last, the review also describes several 
products that have been formulated with the use of whole macroalgae or extracts, along 
with their claimed cardiovascular-associated benefits. 
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1. Introduction 
1.1. Cardiovascular Diseases (CVDs) 
CVDs are a group of disorders of the heart and blood vessels, which include coronary heart  
disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart 
disease and deep vein thrombosis and pulmonary embolism [1]. Overall, CVDs represent the main 
cause of death worldwide, with an estimated number of 17.5 million in 2012 (i.e., 31% of the global 
deaths). From those, approximately 6.7 and 7.4 million deaths were due to coronary heart disease and 
stroke, respectively. These two diseases are projected to remain the leading causes of death in the 
coming years and, according to the World Health Organization (WHO), about 23.6 million people will 
die from CVDs in 2030 [2]. 
Although there are some non-modifiable risk factors for CVDs such as family history, ethnicity and 
age, most CVDs arise as a consequence of modern-society habits, including an unhealthy diet, physical 
inactivity, tobacco use and harmful use of alcohol [3]. These behavior risk factors are normally 
reflected in individuals by a dyslipidemia, raised blood pressure, overweight and obesity. Considered 
as traditional biomarkers of CVDs diseases, these parameters are normally screened when evaluating 
the risk of developing CVDs. Still, the recent growing understanding of multiple biological pathways 
underlying CVDs, including those of inflammation and oxidative stress [4,5], allowed the identification 
of additional biomarkers that can be useful for a more authentic and reliable estimation of 
cardiovascular risk, as well as to monitor the efficacy of treatments and to develop new 
pharmacological tools [6]. 
For the last two decades, policies and key actions have been developed in order to effectively 
control the fast growing burden of CVDs worldwide. Programs offering healthy choices affordable and 
available, stimulating a healthy life style in populations are a main preemptive approach [7]. In this 
context, dietary interventions such as reduction of salt in the diet, consuming of fruits and vegetables, 
food enriched in unsaturated fats and potassium, are accepted as strongly associated with a decreased 
risk for CVDs [8]. 
1.2. Relevant Macroalgae Components in the Area of Functional Food 
Seaweeds, i.e., marine macroalgae are presently pointed out as the plant-based food of the future [9], 
since besides not competing with food crops for the use of arable land and fresh water resources, they 
are a good supply of key nutrients including carbohydrates, protein and minerals [10,11], as well as a 
rich source of health-promoting compounds capable of acting on a wide spectrum of disorders and/or 
diseases [10,12,13]. This latter fact is becoming particularly evident as macroalgae are presently under 
the spotlight of many investigations. Note also that macroalgae have been consumed as food in East 
Asia (mostly in Japan, China and Korea) since ancient times and epidemiological studies associating 
their regular consumption to several health benefits have been reported [14]. Remarkably, the Japanese 
have the longest life expectancy in the world and the lowest rates of CVDs, and these scores have been 
partly associated with their different dietary patterns, which include the regular consumption of 
macroalgae [15,16]. 
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All these facts are pushing the Western culture to increase the interest in the manufacturing and 
consumption of high-value products derived from macroalgae, with the main aim of taking advantage 
of their potential health effects. Indeed, the global functional food market, evaluated for the year 2013, 
was around $168 billion, and forecast to be more than $305.4 billion by 2020 [17], is believed to be 
one of such exploiting opportunities where direct applications of seaweeds, crude extracts or purified 
fractions of seaweeds might hold potential. 
Soluble dietary fibers, peptides, phlorotannins, carotenoids and minerals are amongst the most 
promising macroalgae’s compounds in the area of functional foods/nutraceuticals. Major soluble fibers 
include alginate from brown macroalgae, carrageenan and agar from red macroalgae, which overall 
can represent up to half of seaweed’s dried weight (DW). This fact renders macroalgae a leading 
position with regard to fiber content, ahead of the majority of fruits and vegetables [18–20]. This is 
even more notable because human consumption of fiber-enriched products from macroalgae origin are 
documented to promote heath benefits, including the prevention of colon cancer, type II diabetes, 
obesity and CVDs [10,21]. 
Along with the major soluble fibers mentioned above, fucoidans, i.e., sulfated polysaccharides 
composed of L-fucose and sulfate ester groups, and ulvans (i.e., sulfated polysaccharides mainly 
composed of glucuronic acid and iduronic acid units together with rhamnose and xylose sulfates) [13] 
are also central when it comes to the potential applications in the formulations of functional foods, 
since over the last few years they have been closely associated to numerous health benefits [22,23]. 
Note that being natural polysaccharides, their structure is of course very dependent on the species of 
seaweed. Still, the composition and bioactivities of the final product are also affected by other factors 
like the method of extraction [13,24]. 
Phlorotannins are phenolic compounds exclusive to brown algae that consist of dehydro-oligomers 
or dehydro-polymers of phloroglucinol (Figure 1), occurring in a wide range of molecular 
arrangements including variations in the nature of the structural linkages between phloroglucinol units 
(aryl-aryl or diaryl ether bonds) and the number of hydroxyl groups [25,26]. These phenolic 
compounds are known to accumulate mainly in the cell cytoplasm in specialized secretion vesicles 
named physode, representing up to 25% of their DW [26]. Although studies focusing on the 
characterization and bioactivity of individual phlorotannins are still very limited, several of these 
compounds have already been isolated and characterized (e.g., phloroglucinol, eckol, 
phlorofucofuroeckol A and dieckol, see Figure 1) and claimed to provide a wide range of biological 
activities, including potent antioxidant effects [27]. 
Macroalgae lipids also have potential applications for exploitation. Seaweeds’ lipids represent only 
1%–5% of DW, but almost half of that fraction is polyunsaturated, where omega-3 and omega-6 fatty 
acids like eicosapentanoic acid and arachidonic acid are abundant [19]. In addition to this, the 
carotenoid fucoxanthin (Figure 1) has great commercial value since it is accepted to be helpful in the 
treatment of obesity, while also decreasing the risk of other associated diseases [28]. 
Besides having high proteic content (10%–47% for red and green) [13,14], macroalgae also 
contains all essential amino acids, which are undoubtedly of importance for health maintenance. In 
addition to that, macroalgae peptides containing 3–20 amino acid residues are emerging as bioactive 
constituents, since distinct authors reported their beneficial actions against several disorders like 
oxidative stress, hypertension, thrombosis and cancer [10,12,29]. 
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Macroalgae also contain an incomparable wealth of minerals (this may vary from 8% to 40% of algae 
DW) and have therefore been employed as mineral additives to feed and food supplements [30]. Worth 
noting is, amongst others, their high content in essential minerals namely Na, K, Mg, P, I, Zn and  
Fe [11,30]. Indeed, most algae contain high levels of Na and K, but their Na/K ratios are usually  
low [11,30], which is important to compensate the modern Western diets, typically rich in NaCl. 
Furthermore, many edible macroalgae have higher contents of Mg than terrestrial plants and animals 
and some of them are particularly enriched in Ca (up to 2 g/100 g DW) and iodine (up to 0.5 g/100 g 
DW) [30,31]. 
 
Figure 1. Chemical structures of some phlorotannins (phloroglucinol, eckol, 
phlorofucofuroeckol-A and dieckol) and fucoxanthin. 
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2. Overview of Relevant Biological Pathways Underlying CVDs 
Research studies and accumulated clinical evidence indicate that risk factors of CVDs overlap and 
intertwine, overall contributing to the onset and growth of the disease. For example, obesity 
contributes to or directly causes most other modifiable risk factors, including dyslipidemia and 
hypertension [32] and these in turn are closely related to atheroclerosis and thrombosis. Together with 
behavior factors, the non-modifiable markers contribute to the onset and exacerbation of CVDs through 
a cascade of mechanisms including vascular inflammation, oxidative stress, hypercoagulability and 
activation of the sympathetic and renin-angiotensin systems [4,33]. Attending to the huge complexity 
of events underlying CVDs, this review will mainly address lipid-metabolic changes and hypertension 
biomarkers, along with their major complications. 
Dyslipidemia is as a major risk factor for CVDs, being in general characterized by an elevated 
fasting and postprandial concentration of total triglycerides (TG) and of free fatty acids, in 
combination with the preponderance of low-density lipoproteins cholesterol (LDL-C) along with low 
levels of high-density lipoproteins cholesterol (HDL-C) and of apolipoprotein B (apo B) plasmatic 
concentrations [5]. Note that HDL-C exerts cardioprotective effects through the uptake of cholesterol 
from peripheral tissues and arterial wall to the liver and by preventing LDL oxidation. In opposition, 
hypertriglyceridemia leads to an incremented formation of small dense LDL, causing the delay of their 
metabolization and consequent atherogenicity [34]. The latter, in combination with endothelial 
damage, are key events in the most common pathological processes underlying CVDs [35,36]. 
Along with dyslipidemia, hypertension is one of the major, yet controllable, highly significant risk 
factors for the development of all manifestations of CVDs and the main predictor of stroke. It is 
noteworthy that this condition can also arise from dyslipidemia, through endothelial dysfunction and 
the loss of physiological vasomotor activity of endothelium, which ultimately result in increased blood 
pressure and hypertension [35]. 
By definition, hypertension is established when the systolic blood pressure (i.e., the maximum 
blood pressure during contraction of the ventricles) is above 140 mmHg and/or the diastolic blood 
pressure (i.e., the minimum pressure recorded just prior to the next contraction) is above 90 mmHg [37]. 
Mechanistic causes of hypertension include the reduction of glomerular filtration rate or increased renal 
tubular reabsorption of salt and water, the excessive activation of renin-angiotensin-aldosterone and 
sympathetic nervous systems, increased formation of reactive oxygen species (ROS), the vasoconstrictor 
peptide endothelin and of inflammatory cytokines and decreased synthesis of endothelial nitric oxide. 
Other important factors for hypertension include an excessive weight gain and dietary factors [38,39]. 
The intake of minerals and, in particular that of sodium/potassium (Na/K) ratio is believed to be 
vital in blood pressure control. It is known that the dietary NaCl ingestion increases arterial 
constriction and peripheral vascular resistance, thus elevating the blood pressure [40]. In opposition, it 
is well established that K intake leads to the decrement of blood pressure and thus prevents 
hypertension-associated complications [41]. In this way, WHO recommends a K intake of at least  
3.51 g/day and less than 2 g Na/day (equivalent to 5 g salt/day) in adults [41,42]. Besides Na and K, 
magnesium has also been proven to prevent high blood pressure and metabolic syndrome [43]. 
Additionally, its deficiency has been suggested to play a role in the onset of type II diabetes and in 
lipid metabolic changes, thus consequently contributing for atherosclerosis [43,44]. 
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Along with minerals, the renin-angiotensin-aldosterone system has an important function in 
hypertension, as its activation results in the conversion of angiotensin I to angiotensin II, being the 
latter a potent vasoconstrictor [45,46]. The clinical use of drugs acting in this system is frequent and 
includes: (i) inhibitors of angiotensin-converting-enzyme (ACE-I); (ii) angiotensin II receptor blockers 
(ARBs); and (iii) renin inhibitors. Captopril, cilazapril, enalapril, perindopril, lisinopril and ramipril are 
authorized ACE-I inhibitor drugs, which competitively block the conversion of angiotensin-I to 
angiotensin-II [47], while ARBs (e.g., losartan and valsartan) act by competitive antagonism of the 
angiotensin II receptors [48]. These drugs are used in cases of moderate hypertension and are 
prescribed alone or in combination with other antihypertensive drugs [46]. Direct renin inhibitors are a 
novel class of antihypertensive drugs developed to inhibit the renin-angiotensin-aldosterone axis and 
consequently reduce the angiotensin II concentrations by inhibition of the conversion of angiotensinogen to 
angiotensin-I [49]. 
Hypertension and dyslipidemia are also the most common remediable risk factors for 
atherosclerosis, which is a main cause of the most common pathological process leading to CVDs 
including myocardial infarction, heart failure and stroke [33,50]. The atherosclerotic plaque is 
characterized by an increasing lesion grown from a fatty streak to an atheroma, with a fibrous cap. In 
this process, the passage of lipids into the subendothelial space comes after endothelial damage. It is 
accepted that endothelium stress can be caused by several factors, including an excess of ROS, or the 
exposure to toxic agents (e.g., oxidized LDL (oxLDL)), to infectious agents or advanced glycosylated 
end products (the result of an oxidation reaction with glucose that are found in the blood of diabetics), 
as well as by hypertension and its proinflammatory effects (smooth muscle lipoxygenase activity and 
oxide radical formation, among others) [36,50]. 
The injury of endothelium causes an increase of prothrombotic factors, proinflammatory adhesion 
molecules (e.g., vascular adhesion molecule-1 (VCAM-1)), proinflammatory cytokines (interleukines 1 
and 6 (IL-1 and IL-6, respectively), and tumor necrosis factor alfa (TNF-α)), chemotactic factors 
(MCP-1), ROS production and increase of leukocyte adhesion. Other important feature is the 
diminished release of nitric oxide (NO•) into the arterial wall, which is known to contribute to 
endothelial homeostasis through diverse mechanisms, including modulation of vascular tone [51,52]. 
All these events allow amplifying the inflammatory cascade in atherosclerotic lesions, which is 
characterized by an immunologic and inflammatory infiltrate composed of distinct cells, including 
monocyte-derived macrophages, smooth muscle cells and T lymphocytes [53]. The development and 
progression of the lesion depends on the interaction of these cells with the connective tissue, ending on 
the formation of stable or instead, vulnerable atherosclerotic plaques. The latter are typically 
characterized by active proteolytic enzymes, including metalloproteinases (MMPs) [45]. 
Lesions in vulnerable plaques can progress to the thinning of the fibrous cap rendering it susceptible 
to rupture and thrombosis. In case of rupture, the inflammatory signaling (e.g., T lymphocytes and 
macrophages) induce the formation of the procoagulant tissue factor, promoting the thrombus 
formation which is an important complication of atherosclerosis [45,52]. Briefly, local thrombus 
produces thrombosis-associated mediators (e.g., serotonin, thromboxane A2, thrombin), which cause 
local and disseminated vasoconstriction. Besides coagulation, platelet activation results in a  
well-coordinated series of events which includes the trapped platelets to subendothelium, recruitment 
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and activation of additional platelets and the formation of platelet aggregates, which overall contribute 
for acute atherothrombosis [54]. 
3. Evidences of Protective Effects of Seaweeds with Impact on CVDs 
3.1. Dyslipidemia 
The common side effects of the current synthetic lipid-lowering drugs, i.e., hepatic and/or 
rhabdomyolysis [55], have increased the tendency to move toward traditional and alternative  
treatments [56]. In this field, the diet supplementation of seaweeds and/or extracts might have a 
potential protective role. This is supported by the fact that epidemiological observations show 
satisfactory results when associating the consumption of seaweeds, medicinal plants and fruits to the 
prevention of hyperlipidemia in many societies [57]. Having this in mind, the potential effect of 
distinct macroalgae and/or its isolates in hyperlipidemia control has been largely tested in animal 
models. Due to the high number of reported studies in this topic, only the most recent ones have been 
selected for this review. 
When supplementing the diets of hypercholesterolemic Wistar rats with 21% of Himanthalia elongata 
or 23% of Gigartina pistillata, Villanueva and coworkers [58] showed that Himanthalia-treated rats 
presented a reduction in the plasmatic levels of TG (28%) while increasing those of HDL-C (20%). In 
turn, the Gigartina-supplemented diet produced a significant decrease of 31% in TG, 18% in total 
cholesterol (TC) and 16% in LDL-C [58]. Identical effect was observed in studies using diets 
supplemented with tropical green seaweed (5% of dried Derbesia tenuissima (DT)). DT did not change 
total body fat mass but it could decrease the plasmatic levels of TG by 38% and TC by 17% [59]. 
In addition, the diet supplementation of high-cholesterol/high-fat (HF) Sprague-Dawley rats with 
10% freeze dried red seaweed Gracilaria changii (G. changii) powder for eight weeks significantly 
lowered the plasmatic TC, LDL-C and TG contents by 40.34%, 35.95% and 30.91% respectively, as 
compared to the HF-induced rats group although no effect on HDL-C could be observed [60]. Its 
hypolipidemic action was comparable to statin. As suggested by the authors, one of the potential 
mechanisms of action explaining the hypolipidemic effects of G. changii might be due to its high 
dietary fiber (61.29%) [60]. Supplementation of G. changii to the normal rats showed less significant 
effect on the plasma TC, HDL-C, LDL-C and TG levels [60]. These differences suggest that this 
seaweed is probably more effective for hyperlipidemia treatment purposes instead of preventive ones. 
In addition, brown algae Ecklonia cava supplementation dose dependently suppressed TG, TC, and 
LDL-C concentrations in the serum in both normal and STZ-diabetic mice (supplementation of 5% of 
seaweed in diabetic mice causes a decrease in serum levels of 72%, 53%, and 78%, respectively) but 
failed to affect HDL-C concentrations in normal mice [61]. 
For the last years, there are also distinct works reporting positive effects on lipid metabolism as a 
result of diet supplementation of extracts obtained from macroalgae. Ruqqia et al. [62] showed that 
amongst the ethanol extracts of 13 seaweed species, those of Jolyna laminarioides and Sargassum 
binderi exhibited comparable hypolipidemic potential to common hypolipidemic drugs such as 
bezafibrate and fenofibrate (through decrement of TC, TG and LDL-C) in diet-induced hyperlipidemic 
rats and in triton-induced hyperlipidemic rats [62]. The extract from Melanothamnus afaqhusainii was 
Mar. Drugs 2015, 13 6845 
 
 
also moderately active in lowering the levels of TC, TG and LDL-C in triton-induced hyperlipidemic  
rats [62]. Liver and cardiac enzymes like lactate dehydrogenase, alkaline phosphatase, aspartate alanine 
aminotransferase were not adversely affected by administration of these three extracts [62].  
In addition, the ethanol extract of the brown seaweed Iyengaria stellate (10 mg/200 g body weight 
to rabbits for 30 days) showed an overall decrease in total plasmatic lipid levels, although an increase 
in the contents of the liver enzymes alkaline phosphatase, glutamic-pyruvic transaminase (SGPT), 
glutamic oxaloacetic transaminase and γ-transaminase (with exception for SGPT) were also registered [63]. 
Note that as SGPT is a more specific indicator of liver injury, the overall results gathered by the 
authors suggest that the intake of Iyengaria stellate extract as a hypolipidemic agent should be 
followed by the monitoring of liver enzymes to ensure liver safety. 
Furthermore, Dousip et al. [64] investigated the antihyperlipidemic effect of red seaweed 
Kappaphycus alvarezii and brown seaweed Sargassum polycystum aqueous extracts, as well as their 
synergistic effects, in high-cholesterol diet fed rats. The results showed that Sargassum polycystum 
was more effective in decreasing plasma cholesterol (by 37.52%) when compared to Kappaphycus 
alvarezii or with the mixture of the two extracts, though an increase in plasmatic TG levels by 16.66% 
was also observed. In turn, the Kappaphycus alvarezii extract most effectively decreased the TG levels 
by 40.11% and the mixture of the two extracts further increased HDL-C (by 56.71%). All the three 
tested conditions (individual extracts or mixture) were able to reduce LDL-C levels when compared to 
the high-cholesterol group [64]. Overall, hypercholesterolemic rats fed with the mixture of the extracts 
had the lowest atherogenic index among all groups [64]. 
Besides the evidences of dietary supplementation of seaweeds and/or crude extracts on lipid 
metabolism, many authors have also been described positive effects for purified fractions and/or 
isolated compounds. Amongst them, the majority of the works have been focusing two major groups of 
compounds, namely seaweeds’ sulfated polysaccharides and lipids. Some recent examples are 
described below. 
Borai et al. [65] reported that the oral administration of sulfated polysaccharides (SP) from  
Ulva fasciata to induced-hypercholesterolemic rats for four consecutive weeks did not exert any side 
effects and, simultaneously, it caused a significant decrement in serum lipid profile by reducing the 
plasmatic TC, TG, LDL-C and of very low density lipoproteins-cholesterol (VLDL-C). Notably, the 
scores for Ulva fasciata ulvans effects were better than those observed for the reference drug 
fluvastatin [65]. In addition, Hoang and coworkers [66] reported that two types of SP isolated from the 
green alga Monostroma nitidum showed the ability to reduce cellular lipid concentrations in  
lipid-loaded hepatocytes, when compared with controls, being this reduction accompanied by a 
reduced expression of cholesterol synthesis genes and an increment in the expression of genes 
dictating cholesterol degradation, LDL uptake and peroxisomal β-oxidation. 
Another relevant work focusing the effects of ulvans in lipid metabolism has been performed by 
Hassan et al. [67]. These authors described that the intragastric administration of Ulva lactuca sulfated 
polysaccharides to dietary-induced hypercholesterolemic rats could cause a more evident effect in the 
increment of HDL-C level (by 180%) when compared to that induced by its oral administration [67]. 
This paves the way for discussion of the effect of the administration mode and how to take advantage 
of this difference in results. 
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Along with ulvans, fucoidans have been largely evaluated as antihyperlipidemic agents. Recently,  
a fucoidan extracted from the brown seaweed Sargassum henslowianum and whose structure was 
established as an α(1→3)-linked L-fucopyranose backbone with sulfate groups mostly present at C-2,  
C-4 and occasionally at C-3, was tested in an obese mice model. The administration of this fucoidan at 
a dose of 100 mg/kg P/day to the animals caused a decrement in the plasmatic levels of cholesterol, TG 
and LDL-C [68]. Unfortunately, definite conclusions on the effective effect of this polysaccharide still 
requires additional studies on dosage, administration time, in between other parameters. 
In addition, Kim et al. [69] have recently demonstrated that the dietary supplementation of a 
commercial fucoidan (Haewon Biotech, Inc., Seoul, Korea) induced a significant decrease on the 
plasmatic levels of TG, total cholesterol and of LDL-C. As reported by the authors, the beneficial 
effects of the fucoidan were probably partially associated to the down-regulation of adipogenic 
transcription factor [69]. 
Carrageenans, another type of sulfated polysaccharide typically present in red algae, were recently 
used in a clinical trial study. Patients with ischemic heart disease (IHD) were reported to exhibit a 
significant effect on lipid profile by a short-term carrageenan supplement [70]. In fact, the prophylactic 
administration of the carrageenan food supplement in the complex therapy of IHD patients could 
significantly decrease the plasmatic TC levels by 16.5% and LDL-C by 33.5% as compared with the 
baseline measurements (background therapy control and experimental groups) [70].  
Amongst the macroalgae lipids, fucoxanthin and fatty acids are widely mentioned when it comes to 
dyslipidemia regulation. Notably, the beneficial effects of fucoxanthin on cardiovascular diseases were 
recently reviewed by Gammone et al. [71]. In agreement with distinct reported studies, these authors 
highlighted that fucoxanthin metabolites (amarouciaxanthin A and fucoxanthinol) are the active in vivo 
forms of fucoxanthin and that their ability in regulating lipids plasmatic levels are mainly due to their 
antioxidant activity [71]. In addition, fucoxanthin and its metabolite fucoxanthinol are accepted to 
exhibit extra-metabolic benefic effects, including the regulation of polyunsaturated fatty acids (PUFA) 
biosynthesis by the promotion of the upregulation of enzymatic activities related to the bioconversion 
of omega-3 PUFA and omega-6 PUFA to docosahexaenoic acid (DHA) and arachidonic acid (AA), 
respectively [72–74]. Furthermore, it has been demonstrated that both these compounds could induce a 
decrease in the content of eicosapentaenoic acid (EPA) on cultured rat hepatoma BRL-3A, thus 
suggesting a down-regulation of metabolic enzymes such as fatty acid desaturase and elongase [75].  
In rodents, fed fucoxanthin promotes the synthesis of DHA in the liver [72], resulting in the 
improvement of the lipid profile since this acid inhibits the synthesis of thromboxane A2 and enhances 
the production of prostacyclin, a prostaglandin that produces vasodilation and less sticky platelets [76]. 
As previously mentioned, fatty acids from seaweeds may have itself beneficial properties relevant 
to cardiovascular disease since they are good sources of the long-chain omega-3 PUFAs EPA and 
DHA acids [74,77–80], which in turn promote beneficial effects in serum EPA, TC and TG levels and 
in LDL-C/HDL-C ratio [77,81,82]. As demonstrated in KK-Ay mouse, DHA and AA levels are 
significantly increased by the feeding of lipids from Sargassum horneri and Cystoseira hakodatensis, 
but not by those obtained from Undaria pinnatifida [83]. As suggested by the authors, this difference 
can be due to the higher fucoxanthin content in the first two seaweeds. The authors have additionally 
reported that the plasmatic levels of TC, HDL-C and phospholipid of mouse fed with seaweeds lipids 
were significantly increased while those of hepatic cholesterol and triacylglycerol were decreased as 
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compared with the control group [83]. The increase of serum cholesterol levels by fucoxanthin, in KK-Ay 
mice, was studied by Beppu et al. [84]. The results suggest that fucoxanthin exerts its effects on 
cholesterol metabolism and in the transport system by down-regulation of the LDL receptor and the 
class B type 1 scavenger receptor, along with inducing sterol regulatory element binding protein 
expression [84]. Further studies however are required for clarifying whether the responses to cholesterol 
metabolism are specific for rodents or extended to Human. 
3.2. Hypertension 
The preventive hypertensive effects of seaweeds have since ever been associated with their richness 
in dietary fibers and mineral contents and, although reported literature regarding this issue is clearly 
scarce when compared to that dealing with dyslipidemia, in vitro and in vivo studies support this 
association. In addition, recent literature data suggests that bioactive components like fucoxanthin, 
phlorotannins and peptides can also play a role in seaweeds’ antihypertensive effects. 
As mentioned before, inhibition of ACE-I is a well-established approach in the treatment of 
hypertension and, because of that, many authors have screened the potential of seaweeds in inhibiting 
this enzyme, either using crude extracts, purified fractions and/or isolated components (see selected 
examples in Table 1). 
Cha et al. [85] screened the in vitro ACE-I inhibitory activity of methanol and aqueous extracts 
from twenty-six red Korean algae, obtained at 20 °C or at 70 °C. The authors have found several 
potential extracts, with IC50 values for ACE-I in the range of 12.21–124.69 μg·mL−1, being the lowest 
value found for the aqueous extract of Lomentaria catenata at 20 °C. In addition, Jung et al. [86] found 
that among the ethanol extracts of ten Korean seaweeds, including four Rhodophyta (Gelidium 
amansii, Gigartina tenella, Porphyra tenera and Chondria crassicaulis), five Phaeophyta (Ecklonia 
stolonifera, Ecklonia cava, Hizikia fusiforme, Pelvetia siliquosa and Undaria pinnatifida) and one 
Chlorophyta (Capsosiphon fulvescens), those of E. cava, E. stolonifera, P. siliquosa, G. tenella and  
U. pinnatifida were the most promising in targeting ACE-I, all causing inhibition above 50% at  
163.9 μg·mL−1. Since several purified fractions and isolated phlorotannins from the extract of  
E. stolonifera also exhibited marked ACE-I inhibitory activity, the authors concluded that 
phlorotannins, in particular eckol, phlorofucofuroeckol A and dieckol could be partially responsible for 
the protective activity of the crude extract [86]. 
In another study, Wisesingh and coworkers [87] also suggested that phlorotannins could be key 
constituents of extracts when concerning ACE-I targeting. The authors demonstrated that the ethanol 
extract of E. cava was the most active against ACE-I activity when compared to other organic extracts 
obtained with ethyl acetate, chloroform, hexane or diethyl ether. Besides, they reported that the 
isolated phlorotannins from this seaweed were active against ACE-I. 
Antioxidants, including phlorotannins and fucoxanthin, were also recently shown to be components 
of Saccharina japonica and Sargassum horneri oils, either obtained by environmental friendly 
supercritical-CO2 with ethanol as a co-solvent or by conventional extraction using ethanol, hexane or a 
(1:1, v/v) mixture of acetone:methanol. All the extracts exhibited moderate-to-high activity against 
ACE-I, and authors have suggested that this activity could be attributed in part to fucoxanthin, 
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although no direct correlations between its concentration in the extracts and the inhibitory activity 
were observed.  
Recently, distinct studies applying proteolytic enzymatic digestion to seaweeds has led to detection 
of a number of renin- or ACE-I-inhibitory bioactive peptide. Examples of potential peptides have been 
described for red macroalgae (e.g., from Porphyra columbina, Porphyra yezoensis, and Palmaria 
palmata), as well as for green algae (Caulerpa microphysa) and brown algae (Undaria pinnafita) 
(Table 1). As seaweed hydrolysates consist of a complex mixture of constituents and the amino acid 
sequence of bioactive peptides in ACE-active hydrolysates has not been commonly determined, more 
experimental data should be gathered in order to allow solid conclusions on structural-active relations. 
However, according to Suetsuna and coworkers [88], the presence of Tyr residues in dipeptides seems 
to improve their ability of targeting ACE-I. 
Table 1. Selected studies reporting inhibitory abilities of seaweeds extracts and isolates on 
the renin-angiotensin-system. 
Seaweed Species Extraction Inhibition Ref
ACE-I inhibition of extracts 
Twenty-six red algae 
MeOH and Aq 
Ext 20 °C and  
70 °C 
Aq Ext 20 °C IC50 (µg/mL): Lomentaria catenata = 13.78; Lithophyllum 
okamurae = 12.21; MeOH Ext 20 °C IC50 (µg/mL): Ahnfeltiopsis 
flabelliformis = 13.84; Laurencia okamurae = 106.15; MeOH Ext70 °C: 
Bonnemaisonia hamifera, Grateloupia filicina, Sinkoraena lancifolia, 
Grateloupia lanceolata, Gracilaria vermiculophylla and L. okamurae 
ranging from 25.82 to 124.69 
[85]
Ten Korean 
seaweeds  
EtOH Ext 
Ecklonia stolonifera, E. cava, Pelvetia siliquosa, Undaria Pinnatifida and 
Gigartina tenella: above 50% inhibition of ACE at 163.93 µg/mL 
[86]
Ecklonia cava 
EtOH, EtAc, 
CHCl3, Hex, DE 
Best inhibition for EtOH Ext, IC50 = 0.96 mg/mL [87]
ACE-I inhibition associated with antioxidants 
Ecklonia stolonifera 
Purified 
Phlorotannins 
Best inhibition recorded for eckol, dieckol and phlorofucofuroeckol.  
IC50 (μM): eckol = 70.82; phlorofucofuroeckol A = 12.74; dieckol = 34.25 [86]
Ecklonia cava 
Purified 
Phlorotannins 
IC50 (mM): phloroglucinol = 2.57 ± 0.09; eckol = 2.27 ± 0.08;  
triphlorethol-A = 2.01 ± 0.36; dieckol = 1.47 ± 0.04;  
eckstolonol = 2.95 ± 0.28 
[87]
Saccharina japonica 
(SJ) Sargassum 
horneri (SH) 
Supercritic CO2 
vs. Acet: MeOH 
IC50 (µg/mL): SJ CO2 Ext = 0.89 ± 0.07; SJ Acet:MeOH Ext = 1.05 ± 0.14; 
SH CO2 Ext = 0.97 ± 0.11; SH Acet:MeOH Ext = 1.28 ± 0.50; 
[89]
ACE-I or Renin inhibition associated with peptides 
Porphyra columbina 
Enzymatic in 
thermostatic 
reactor (A/AF) 
ACE-I IC50 (g/L): A = 1.2 ± 0.1; AF = 1.7 ± 0.0 [90]
Porphyra yezoensis 
pH and 
enzymatic  
ACE-I IC50 (g/L): 1.6 [91]
Palmaria palmata Papain  
Ile-Arg-Leu-Ile-Ile-Val-Leu-Met-Pro-Ile-Leu-Met-Ala Renin inhibitory 
bioassay: ↓ renin activities by 58.97% (±1.26) at 1 mg/mL. [92]
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Solieria chordalis 
(SC) Palmaria 
palmata (PP) 
Chymotrypsin 
(ChTr) or trysin 
(Tr) 
<10 kDa fractions of SC: hydrolyzed with ChTr (IC50 ACE 3.50 mg/mL) 
or Tr (IC50 ACE 20.34 mg/mL); <10 kDa fractions of PP: hydrolyzed with 
ChTr (ACE IC50 460.05 mg/mL) 
[93]
Caulerpa 
microphysa 
Pepsin, alcalase, 
flavourzyme 
ACE-I IC50 (mg/L): pepsin = 0.20; flavourzyme = 29.74; alcalase = 31.71 [94]
Undaria pinnafida Pepsin  
ACE-I IC50 (µM): Ala-Ile-Tyr-Lys = 213; Tyr-Lys-Tyr-Tyr = 64.2;  
Lys-Phe-Tyr-Gly = 90.5; Tyr-Asn-Lys-Leu = 21 
[95]
Undaria pinnatifida 
Aq hot Ext 
dyalisis, 
chromatography 
ACE-I IC50 (µM): Tyr-His = 5.1; Lys-Trp = 10.8; Lys-Tyr = 7.7;  
Lys-Phe = 28.3; Phe-Tyr = 3.7; Val-Trp = 10.8; Val-Phe = 43.7;  
Ile-Tyr = 2.7; Ile-Trp = 12.4; Val-Tyr = 11.3 
[88]
ACE—angiotensin I converting enzyme; Acet—acetone; Aq—aqueous; Ext—extract; DE—diethyl ether; 
EtAc—ethyl acetate; EtOH—ethanol; Hex—hexane; MeOH—methanol; ↓ decrement. 
Because non-invasive measure of blood pressure in lab animals is a difficult task, this parameter has 
also not been widely screened when evaluating the beneficial effects of the dietary supplementation of 
seaweeds or isolates in CVDs-related animal models. Still, some authors described the  
diet-supplementation of seaweeds and/or seaweed isolates in blood pressure (see resume of selected 
studies in Table 2). 
Table 2. Selection of studies that include the assessment of blood pressure or antioxidant, 
anti-inflammatory or endothelium restoring as a consequence of diet supplementation of 
seaweeds or isolates, as evaluated in vivo models. 
Seaweed Species (Extract) Model Dose Effects Ref.
Ulva ohnoi (UO)  
Derbesia tenuissima (DT) 
High-carbohydrate,  
HF diet-fed rats 5% 
for 8 weeks 
UO: ↓ total final body fat mass by 24% and sBP by 29 mmHg; ↑ Glc 
utilization and insulin sensitivity;  
DT: ↓ TG by 38% and TC by 17% 
[59]
Ulva linza (UL) Lessonia 
trabeculata (LT) 
High-sucrose, HF 
diet-fed rats|400 
mg·kg−1 for 8 weeks 
UL, LT: ↓ levels of intra-abdominal fat, arterial BP, insulin resistance, 
TC, TG, SOD; ↓ liver expression levels SOD and GPx and ↑ CAT in 
control groups and ↓ in algae-fed rats; LT: ↓ GPx activity 
[96]
Gracilaria changii  
HF, HC diet-induced 
rats|5% and 10% for 
8 weeks 
5%: ↓ TC (−39.19%), LDL-C (−36.36%), and TG (−25.45%);  
10%: ↓ TC, LDL-C and TG content by 40.34%, 35.95% and 30.91%, 
respectively; lowest AI;  
5% and 10%: in plasma = ↓ LipPerox; ↓ AST and ALT levels; in 
erythrocyte = ↑ SOD, CAT and GSH-Px 
[60]
Not detailed 
Healthy children 
from 3 to 6 years diet 
including seaweed 
intake using 3-day 
dietary records 
Cross-section study in healthy preschoolers: Girls with higher seaweed 
intake had significantly lower systolic BP (102.4, 99.2 and 96.9 mmHg 
for girls with the lowest, middle and highest tertiles of seaweed intake, 
respectively); seaweed intake was negatively related to dBP in boys 
and to sBP in girls. 
[97]
Undaria pinnatifida (UP) 
Men/Women with 
MS|Gr1:1 month 
(m) 4 g/day UP; 
Gr2: 1 m 4 g plus 1 
m g/day UP (pills) 
Randomized double-blinded placebo-controlled trial.  
Gr2: ↓ systolic BP 10.5 mmHg after a month of 6 g/day seaweed 
(primarily in subjects with high-normal baseline BP); ↓ waist 
circumference for women participants (↓ 2.1 cm after 4 g/day and 
further 1.8 cm after 1 m 6 g/day seaweed). No changes in lipid profile. 
[98]
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Undaria pinnatifida (UP) 
19 patients MS|3.3 
g in capsules  
sBP: ↓ 13 mmHg below the baseline after 4 weeks and 8 mmHg after 
8 weeks. dBP: ↓ 9 mmHg after 4 weeks and 8 mmHg after 8 weeks; 
hypercholesterolemia ↓ 8% by week 4 
[99] 
Extracts 
Sargassum subrepandum 
(MeOH Ext) 
Rats with 
atherogenic diet|100 
mg/kg b.wt 
↓ TC, TG, LDL-C and ↑ HDL-C; ↓ MDA, NO, leptin,  
TNF-alpha levels; ↑ adiponectin level; [100]
Ulva fasciata  
(Ulvans/Aq Ext at 4 °C or 
100 °C plus EtOH pp) 
HC rats|175 mg/kg 
for 4 weeks 
Both Ext: No side effects; ↓ TC, TG, TG, LDL-C and  
VLDL-C; ↓ liver NO•; ↓ ICAM-1 and VCAM-1; ↑ IL-10;  
↓ atherogenic plaques in the aorta more than fluvastatin;  
[65] 
Ulva lactuca  
(Ulvans/Aq Ext at  
100 °C plus EtOH pp) 
HC rats|175 mg/kg 
for 4 weeks 
↓TL, TG, TC, LDL-C and VLDL-C; ↑ HDL-C; ↓ AI, creatine kinase 
and LDH; ↓ liver ALT, AST and ALP activities and serum urea, 
creatinine and urea/creatinine ratio; ↑ hepatic CAT, GSH-Px; ↑ GSH, 
Total thiol levels 
[67] 
Not detailed  
(Low-MW  
Commercial alginates) 
DOCA salt-induced 
hypertensive 
rats|250 or 500 
mg/kg for 30 days 
↓ sBP; dose-dependent normalization of changes induced  
by DOCA salt, with the exception of further increasing  
sodium excretion 
[101]
Gloiopeltis complanata  
(Funoran/Aq hot Ext plus 
various purification steps) 
HC, high-sal fed 
rats|1000 mg/kg for  
20 days 
↓ sBP; ↓ TC, TG, LDL-C, AI; ↑ urine excretion of sodium, chloride; ↑ 
urine Na/K ratio 
[102]
Not detailed  
(Seaweed fiber (SF)) 
Hypertensive 
Patients|Pills with 
0.33 g; 25 min 
before meals for  
4 weeks 
↓ mean and sBP; ↑ plasma renin activity; ↓ urinary secretion of Na, K 
and Na/K ratio 
[103]
Palmaria palmata  
(protein hydrolysate and 
tridecapeptide 
IRLIIVLMPILMA) 
Spontaneously 
Hypertensive  
rats|50 mg/kg b.wt 
After 24 h ingestion: ↓ 34 mm Hg in sBP;  
IRLIIVLMPLIMA: ↓ 33 mm Hg [104]
AI—atherogenic index; Aq—aqueous; ALP—alkaline phosphatase; ALT—alanine aminotransferase;  
AST—aspartate aminotransferase; BP—blood pressure; CAT—catalase; dBP—diastolic blood pressure;  
DOCA—deoxycorticosterone acetate; EtOH—etanol; Ext—extract; Glc—glucose; Gr—group; GSH—hepatic 
reduced glutathione; GSH-Px—glutathione peroxidase; HC—high cholesterol; HDL-C—high density 
lipoprotein cholesterol; HF—high-fat; LDL-C—low density lipoprotein cholesterol; iCAM—intercelular 
adhesion molecule-1; LipPerox—lipid peroxidation; MDA—malonaldialdehyde; MeOH—methanol;  
MS—metabolic syndrome; NO—nitric oxide; pp—precipitation; sBP—sistolic blood pressure SOD—superoxide 
dismutase; TC—plasma total cholesterol; TG—plasma total triglycerides; VCAM—vascular cell adhesion 
molecule-1; ↓ decrement; ↑ increase. 
When evaluating the response of dietary supplementation of Ulva ohnoi and Derbesia tenuissima  
in a rat model of human metabolic syndrome, Kumar et al. [59] reported that Ulva ohnoi could induce  
a marked decrease in systolic blood pressure (by 29 mmHg), along with a decrease in the final body  
fat mass (by 24%) and the improvement of glucose utilization and insulin sensitivity. On the basis of 
chemical composition of the two algae, the authors have suggested that the better scores of Ulva ohnoi 
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with respect to those induced by Derbesia tenuissima could be due to its richness in soluble fibers and 
magnesium. A similar trend on blood pressure were also registered by Ramirez-Huigera et al. [96], 
when testing the effects of diet-suplementation of Ulva linza and Lessonia trabeculata in rats fed with 
a hypercaloric diet. 
Despite scarce and sometimes inconsistent, the effect of diet supplementation of macroalgae in 
human blood pressure, either in healthy or in hypertensive scenarios has also been evaluated.  
The cross-section studies reported by Wada et al. [97] in healthy Japanese preschoolers allowed to 
observe that girls with higher seaweed intake had lower systolic blood pressure while diastolic bold 
pressure in boys also decreased. Additionally, systolic and diastolic blood pressure in hypertensive 
elderly Japanese patients have been shown to be significantly decreased after daily doses of 5 g of 
dried Undaria pinnatifida powder for eight weeks [99]. The same trend was registered in a randomized 
double-blinded placebo-controlled trial with metabolic syndrome patients (also including 
hypertension) taking daily pill dosages of 6 g of U. pinnafita [98]. 
The benefit of seaweeds’ dietary fiber supplementation in hypertensive rats has also been previously 
demonstrated by distinct authors. Some authors suggested that their positive effects could be due to 
retention of dietary Na [102] or to an enhanced intestinal K absorption [101] or to these two effects in 
simultaneous [103]. It should however be remarked that as the cationic exchange ability of fibers is 
dependent on factors like the type of fiber and the mineral content of the diet, further information 
regarding this topic is still required. 
Antihypertensive abilities of macroalgaes’ peptides have also been investigated in vivo models. 
Fitzgerald et al. [104] showed that the diet supplementation of a tridecapeptide derived from a papain 
digest of Palmaria palmata (IRLIIVLMPILMA, previously shown to be active against renin [92]) 
could cause a decrease in systolic blood pressure of about 33 mmHg in spontaneously-hypertensive 
rats. Further simulation of gastric digestion allowed the authors to conclude that the active forms of 
IRLIIVLMPILMA are probably dipeptides originated along the passage through the gastrointestinal 
tract. In addition, Suetsuna and coworkers have characterized several di- and tetrapeptides from digests 
of Undaria pinnafita [88,95]. Amongst them, the dipetides Tyr-His, Lys-Tyr, Phe-Tyr and Ile-Tyr, as 
well as the tetrapeptides Ala-Ile-Tyr-Lys, Tyr-Lys-Tyr-Tyr, Lys-Phe-Tyr-Gly and Tyr-Asn-Lys-Leu, 
were shown to efficiently decrease the blood pressure of spontaneous hypertensive rats through diet 
supplementation [88,95]. 
3.3. Biological Pathways Underlying Atherosclerotic-Related Events 
As previously referred, the formation and progression of atherosclerotic plaques involves a 
multitude of factors, including oxidative and inflammatory events. In this context, antioxidants and  
anti-inflammatory sources are of interest in the quest for antiatherogenic activity. Still, it is noteworthy 
that only a scarce number of research studies have previously monitored these biological pathways 
when evaluating the potential diet supplementation of macroalgae in atherosclerosis-related models, 
being those studies major tested with extracts or isolated compounds (included in Table 2).  
Besides, structure-bioactive studies are almost non-existent. Because of that, this topic demands  
urgent research. 
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Phlorotannins are one the seaweeds’ bioactive compounds that could hold a potential in this 
particular field. In fact, Costa-Mugica and coworkers [105] demonstrated an effective protection of 
LDL oxidation by phlorotannin-enriched fractions isolated from Halimeda incrassata, as measured in 
two heparin-precipitated LDL models. Moreover, the phlorotannins phloroglucinol, eckol, and dieckol 
(Figure 1) have been shown to protect against proinflammatory responses in human umbilical vein 
endothelial cells (HUVEC) and in an animal model of acute inflammation, in response to the 
endotoxin high-mobility group protein B1 (HMGB1) [106]. Phlorotannins inhibited lipopolysaccharide 
(LPS)-induced HMGB1 release, HMGB1-mediated barrier disruption, the expressions of CAMs and 
the adhesion/transendothelial migration of leukocytes to human endothelial cells. The three phlorotannins 
could also suppress acetic acid-induced hyperpermeability and carboxymethylcellulose-induced 
leukocytes migration in the animal model [106]. Notably, this study also highlighted the importance of 
phlorotannins’ hydroxyl groups regarding the vascular barrier protective effects, since the magnitude 
of protection on HMGB1-mediated hyperpermeability and monocytes adhesion noticed in HUVEC 
cells followed the pattern dieckol > eckol > phloroglucinol and were even lowered when the hydroxyl 
groups of dieckol were replaced by methyl groups. Based on the overall results, the authors 
hypothesized that the presence of hydrogen bond donors and hydrophilic moieties in phlorotannins 
may play a central role in its affinity for membrane receptors on human endothelial cells [106]. 
Besides phlorotannins, fucoxanthin has also been associated to the positive effects of a methanol 
extract of Sargassum subrepandum [100]. In their study, the authors showed that in addition to the 
improvement of lipid profile, the oral administration of the extract in a dose of 100 mg/kg.wt for  
four months caused a marked decrease in serum malonaldialdehyde (MDA, i.e., a oxidative stress 
biomarker) and in the proinflammatory markers leptin and TNF-α levels, with a simultaneous increase 
in the level of adiponectin, i.e., an adipocyte-specific protein that is thought to act as anti-inflammatory, 
anti-atherogenic and insulin enhancer [107]. 
Sulfate polysaccharides, including ulvans, carragenans and fucoidans, are the most exploited 
compounds when regarding the protective effects on atheroclerotic-plaque formation and  
progression-related problems. e.g., Hassan and coworkers [67] proved that the oral supplementation of 
hypercholesterolemic rats with an ulvan purified extract from Ulva lactuca could ameliorate the 
activity of the antioxidant enzymes catalase (CAT), glutathione peroxidase (GSH-Px) and superoxide 
dismutase (SOD) by 110%, 77% and 23%, respectively, when compared with the hypercholesterolemic 
control rats. Apart from that, the authors also described beneficial effects on non-enzymatic antioxidants 
parameters (hepatic reduced glutathione, total thiol and lipid peroxidation), suggesting that the 
defensive effect of ulvan was in part mediated by protection of liver against free radicals. 
The atheropreventive activity of ulvans from Ulva fasciata was also recently reported by Borai and 
coworkers [65]. After the oral administration of crude cold and hot extracts to hypercholesterolemic 
rats extracts at a dose 175 mg/kg body weight for four weeks, the authors registered an improvement 
of serum lipid profile and of the endothelial dysfunction. In particular, in comparison to 
hypercholesterolemic rats, the ulvans-supplemented animals showed a decrease of the NO• liver levels 
of 38.95% and 69.46% (for cold and hot extracts, respectively), while this effect was of 58.19% for the 
reference drug (fluvastatin). Both extracts also caused a significant decrease in the levels of the soluble 
adhesion molecules ICAM-1 and VCAM-1, along with an increase in the amounts of the  
anti-inflammatory marker IL-10 (about 30%, 18% and 34% compared to control, for cold, hot  
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ulvan-enriched extracts and fluvastatin, respectively). In addition, morphometric measurements of 
atherosclerotic lesion in untreated/treated rats showed that the oral supplementation of U. fasciata 
extracts induced a reduction in the medial cross-section area of the aorta (19.50% and 26.46%, 
respectively). This result was also consistent with histological data, which demonstrated that in 
contrast with the untreated rats, those subjected to algae-enriched diet exhibited no oblivious lesions in 
the aorta, showing thin intimae and no visible swelling, endothelial cells basically intact and without 
desquamation, no migration of smooth muscle cells to the under-intimae, no proliferation of smooth 
muscle cells and smooth muscle cells arranged in a regular pattern. 
Amongst SP, fucoidans have very promising biomedical/medical applications with regard to 
atherosclerosis and associated progressive complications. The anti-inflammatory potential of these 
polysaccharides in hypercholesterolemic rats has been reported by Preetha et al. [108], using a hot  
water-extracted fucoidan from Sargassum wightii and a comercial fucoidan from Fucus vesiculosos, 
which overall resulted in almost equally effects. The subcutaneous treatment with the algae fucoidans 
at a dose of 5 mg/kg bwt/day during seven days reduced the increased serum levels of the 
inflammatory biomarkers TNF-α and C-reactive protein, the NO• concentrations in plasma and cardiac 
tissues, as well as the levels of cardiac mRNA iNOS and of COX-2 (two potent proinflammatory 
enzymes). In addition, the authors also demonstrated the anticoagulant effect of these polysaccharides, 
as estimated by the levels of plasmatic fibrinogen, a central protein in the formation of blood clots. 
At this point, one should remark that fucoidans and in general SP have been proved to exert potent 
antithrombotic effects. Indeed, these polysaccharides share common structural features with heparin, i.e., a 
highly sulfated glycosaminoglycan that is widely used in clinical practice as an injectable 
anticoagulant. The anticoagulant activities of SP, along with their inhibition of platelet aggregation and 
thrombolytic activities has been the focus of many investigations and have been recently revised by 
distinct authors [22,109,110], which also highlight the high molecular weight and the high sulfation 
level (particularly with substitution at C-2 or C-2 and C-3 positions of fucose) as positive structural 
factors affecting these properties [22,111]. Still, reported data focusing these benefits do not take into 
account bioacessibility and bioavailability issues, as SP in vivo models have been administered 
subcutaneously (as for the above mentioned work of Preetha et al. [108]) or, in the majority of cases, 
as an intravenous injection. In this context, although there are a growing body of evidences that 
fucoidans and other SP can be partly absorbed [112] or suffer favorable changes by intestinal 
microbiota [113,114], these topics are not elucidated, hampering the understanding if SP exert 
effective antithrombotic activities when orally ingested. 
4. Functional Food with Macroalgae for Promoting Cardiovascular Health 
Although there is no consensual definition for the term “functional food” worldwide, this is vastly 
accepted for foods and food components that have been demonstrated to provide specific health 
benefits beyond the basic nutrition [19,115]. The design of functional foods is hence undoubtedly 
associated to the concept of preventing diseases and/or improving optimal health of consumers, 
besides the basic nutrient needs. 
Given the evidence of the beneficial health effects of seaweeds and/or isolates of macroalgae origin, 
there is a strong case for their inclusion in regular foods (food and beverages), in order to take 
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advantages of their benefits [115–117]. It is expected that the combined efforts of industry and 
research in this field will result in the coming years in a high number of new functional food products 
reaching to the market, including those intended to promote cardiovascular health. 
The development of functional foods with seaweeds for cardiovascular-health promotion have been 
particularly tested in meat-based products [116–118] (Table 3) and patents have also been registered [119]. 
In these products, it is important to improve the fatty acid composition and the content of functional 
ingredients, while reducing contents of cholesterol, fat and salt [117,120]. Distinct authors have 
reported that nutritional values of meat products can be significantly improved by the incorporation of 
whole seaweeds, without hampering quality and sensory properties [118,121–126]. Besides, a 
remarkable work has been done by Schultz-Moreira et al., since along with describing the enhanced 
nutritional value of restructured meat when fortified with seaweeds, they also evaluated distinct parameters 
(e.g., lipid profile, antioxidant enzymes and arylesterase) with impact on cardiovascular system [127–132], 
as demonstrated in hypertensive rats. In addition, Lim et al. [133] also showed that chicken and pork 
patties fortified with Laminaria japonica could improve postprandial plasma glucose and lipids 
profiles in borderline-hyperlipidemic adults. 
Table 3. Selected studies reporting CVDs-related parameters in foods/beverages using 
macroalgae or isolates as ingredients. 
Product Seaweed Species Relevant Results Ref
Meat-based products 
Gel/emulsion 
meat systems 
Himanthalia elongate (HE), 
Undaria pinnatifida (UP), Porphyra 
umbilicalis (PU) at 2.5% or 5%  
↑ water- and fat-binding properties except in the case of 
PU at 2.5%. 
[121]
Gel/emulsion 
meat systems 
Himanthalia elongate (HE), 
Undaria pinnatifida (UP), Porphyra 
umbilicalis (PU) at 5.6% 
All: ↑ n-3 PUFA and ↓ n-6/n-3 PUFA ratio; ↓ Na and  
↑ K, Ca, Mg, Mn, antioxidants ↓ TI by for PU and UP [122]
Low-fat 
frankfurters  
Himanthalia elongata (HE) at 5.5% 
(algae plus 50% substitution of 
animal fat by olive oil) 
Effect of HE add: little effect on lipid and amino  
acid profiles but ↑ dietary fiber content and Ca and ↓ 
Na/K ratios 
[123]
Restructured 
meats 
Himanthalia elongata at 5% 
Effects in hypercholesterolemic rats: ↓ TC;  
↑ expression CYP7A1 and Cu, Zn-SOD; ↓ expression 
CAT, Mn-SOD and GPx; 
[127] 
Restructured 
meats 
Undaria pinnatifida (UP), Porphyra 
umbilicalis (PU) at 5% 
Effects in hypercholesterolemic rats: PU = ↓ TC; ↑ 
expression Mn-SOD and CAT and AE activity;  
UP meat mainly had benefits as antioxidant  
[131]
Restructured 
meats 
Undaria pinnatifida (UP), Porphyra 
umbilicalis (PU) at 5% 
UP moderately ameliorated the lipid profile in 
hypercholesterolemic rats: ↓ TC and VLDL-C  [132]
Restructured 
meats 
Himanthalia elongata at 5% 
Effects on hypercholesterolemic rats: ↑ AE activity;  
↓ VLDL-C, ILDL-C + LDL-C [130]
Pork/chicken 
patties  
Laminaria japonica (LJ) 
(replacement of 2.25 g pork/chichen 
by 2.25 g LJ) 
↓ increased in postprandial glucose blood levels;  
↓ TC and LDL-C [133]
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Others 
Bread 
Tridecapeptide IRLIIVLMPILMA 
from Palmaria palmata at 4% 
Activity against renin IRLIIVLMPILMA maintained 
after baking process 
[134]
Bread Ascophyllum nodosum at 4%  
Single blind cross over trial: ↓ in energy intake at  
a test meal 4 h later; no significant changes in Glc  
and cholesterol 
[135]
Tea 
Ecklonia cava (EC), Undaria 
pinnatifida (UP), Hizikia fusiforme 
(HF), Ulva pertusa (UP) 
ACE inhibition IC50 (mg DW/mL): EC = 5.33 ± 0.24, 
UP = 26.4 ± 1.05, HF = 7.79 ± 0.46; UP = ND 
[136]
AE—arylesterase; ACE—angiotensin I converting enzyme; AI—atherogenic index; CAT—catalase;  
Glc—glucose; IDL-C—intermediate density lipoprotein cholesterol; LDL-C—low density lipoprotein cholesterol; 
PUFA—polynsaturated fatty acids; SOD—superoxide dismutase; TC—plasma total cholesterol;  
TG—plasma total triglycerides; VLDL-C—very low density lipoprotein cholesterol; ↓ decrement; ↑increase. 
Bakery and pasta products are other excellent choices for introducing bioactive ingredients, 
including algae, since they are greatly consumed worldwide. When testing the incorporation of a  
renin-inhibitory Palmaria palmata protein at 4% in bread, Fitzgerald et al. [134] reported that the 
bioactivity was maintained after the baking process and hence concluded that this peptide could be 
used for production of bread with enriched renin-inhibitory capacity, while not affecting the texture or 
sensory properties of the bread to a large degree. 
Hall et al. [135], in a single blind cross trial also reported that addition of Ascophyllum nodosum 
into bread could significantly reduce energy intake at a subsequent test meal and in the total energy 
intake in the 24 h period following consumption of the A. nodosum enriched bread, though differences 
in blood glucose and cholesterol were not significant. The authors however suggested that a long-term 
interventional study should be done in order to establish the real potential of A. nodosum enriched 
bread energy intake as well as in the metabolism of glucose and lipids. 
For the last years, development of beverages with seaweeds and/or extracts has also been the focus 
of distinct investigations and of several patent registrations. Amongst those, Fu and coworkers have 
patented a beverage containing water-insoluble algal dietary fibers (0.01% to 20%) and citric acid, 
sugar, fruit juice, plant thickeners and water, which can prevent from distinct diseases, including 
cardiovascular disorders [137]. Likewise, Kim patented a Hizikia fusiforme fortified drink with 
antihypertensive effects [138], while Korea Bio Polymer Co. Ltd. patented a functional beverage able 
to ameliorate cardiovascular disease [139]. This latter contained Polymann™ (Korea Bio Polymer Co. 
Ltd., Seoul, South Korea), a purified form of polymannuronic acid from the kelp Undaria. 
Besides patents, scientific studies reporting potential effects of functional beverages including 
distinct macroalge has been reported by Nagai and coworkers [136,140]. Overall, these studies 
highlighted that drinks formulated with incorporation of macroalgae, in particular with Ecklonia cava, 
could be of benefit not only because of their minerals and phenolics richness, but also because of their 
ability to target ACE-I. 
In between other products, functional salts containing seaweeds components have been studied [141]. 
Related to this, it is worth noting that there is a commercially available seaweed-derived salt substitute 
for hypertensive patients (Saloni K, from NMR Pharma, India). 
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5. Conclusions 
Seaweeds are a great source of compounds with diverse applications, including in the field of 
cardiovascular-health. This fact renders macroalgae and crude/purified extracts, a potential for 
application as ingredients in the formulation of new functional foods in that health area. Indeed, there 
is evidence that diet supplementation with whole macroalgae or products of macroalgae origin can 
ameliorate several mechanisms underlying the onset and propagation of CVDs. Still, let us remark that 
the challenge of using these ingredients in novel foods should not be restricted to the improvement of 
their nutritional formulations, but instead, efforts should be done in order to test the claimed health 
benefits of the new products. 
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